Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More Details
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Ionis Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IONS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IONS's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: IONS underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: IONS underperformed the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Ionis Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StIonis Pharmaceuticals' (NASDAQ:IONS) Stock Price Has Reduced 42% In The Past Year
1 month ago | Simply Wall StIs Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way?
4 months ago | Simply Wall StAnalysts Are More Bearish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Than They Used To Be
Is Ionis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IONS ($38.03) is trading below our estimate of fair value ($90.84)
Significantly Below Fair Value: IONS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IONS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IONS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IONS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IONS is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (2.9x).
How is Ionis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IONS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IONS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IONS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IONS's revenue (17.6% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: IONS's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IONS's Return on Equity is forecast to be very high in 3 years time (42.8%).
How has Ionis Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IONS is currently unprofitable.
Growing Profit Margin: IONS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IONS is unprofitable, but has reduced losses over the past 5 years at a rate of 10.8% per year.
Accelerating Growth: Unable to compare IONS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IONS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: IONS has a negative Return on Equity (-77.4%), as it is currently unprofitable.
How is Ionis Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: IONS's short term assets ($2.0B) exceed its short term liabilities ($295.1M).
Long Term Liabilities: IONS's short term assets ($2.0B) exceed its long term liabilities ($1.3B).
Debt to Equity History and Analysis
Debt Level: IONS's debt to equity ratio (134.9%) is considered high.
Reducing Debt: IONS's debt to equity ratio has reduced from 258% to 134.9% over the past 5 years.
Debt Coverage: IONS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if IONS's interest payments on its debt are well covered by EBIT.
What is Ionis Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IONS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IONS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IONS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IONS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IONS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brett Monia (60 yo)
Dr. Brett P. Monia, Ph.D., is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been its Chief Executive Officer since January 2020. He serves as Non-Executive Director at DYNACURE SAS since October...
CEO Compensation Analysis
Compensation vs Market: Brett's total compensation ($USD10.96M) is above average for companies of similar size in the US market ($USD6.50M).
Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.
Experienced Management: IONS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: IONS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ionis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ionis Pharmaceuticals, Inc.
- Ticker: IONS
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.361b
- Shares outstanding: 140.96m
- Website: https://www.ionispharma.com
Number of Employees
- Ionis Pharmaceuticals, Inc.
- 2855 Gazelle Court
- United States
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/25 22:38|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.